Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/191974
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Queralt Salas, Maria | - |
dc.contributor.author | Mussetti, Alberto | - |
dc.contributor.author | Muñóz, Carme | - |
dc.contributor.author | Albasanz Puig, Adaia | - |
dc.contributor.author | Patiño, Beatriz | - |
dc.contributor.author | Jimenez Prat, Laura | - |
dc.contributor.author | Gudiol González, Carlota | - |
dc.contributor.author | Parody, Rocío | - |
dc.contributor.author | Sureda, Anna | - |
dc.date.accessioned | 2023-01-09T17:24:41Z | - |
dc.date.available | 2023-01-09T17:24:41Z | - |
dc.date.issued | 2021-02-08 | - |
dc.identifier.issn | 2531-1379 | - |
dc.identifier.uri | http://hdl.handle.net/2445/191974 | - |
dc.description.abstract | Patients undergoing allogeneic stem cell transplantation (alloHCT) require profound immunosuppression is required to preserve graft function and prevent graft-versus host disease (GVHD), resulting in a high risk of infectious complications such as invasive fungal diseases (IFIs). Posaconazole is approved for primary antifungal prophylaxis alloHCT. However, posaconazole is associated with drug-drug interactions which may lead to relevant toxicities limiting it uses in hematological patients. Other triazoles, amphotericine B, and echinocandins can be used in patients at high risk of IFIs. However, there is less evidence supporting the efficacy of these drugs for the prevention of IFIs. | - |
dc.format.extent | 4 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.htct.2021.01.002 | - |
dc.relation.ispartof | Hematology, Transfusion and Cell Therapy, 2021, vol. 44, num. 3, p. 440-443 | - |
dc.relation.uri | https://doi.org/10.1016/j.htct.2021.01.002 | - |
dc.rights | cc-by-nc-nd (c) Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular, 2021 | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Cèl·lules mare | - |
dc.subject.classification | Medicaments antifúngics | - |
dc.subject.classification | Medicina preventiva | - |
dc.subject.other | Stem cells | - |
dc.subject.other | Antifungal agents | - |
dc.subject.other | Preventive medicine | - |
dc.title | Isavuconazole prophylaxis against invasive fungal infections in allogeneic stem cell transplantation: a single-center experience | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 711174 | - |
dc.date.updated | 2023-01-09T17:24:41Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
711174.pdf | 381.19 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License